Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Dividends Paid - CommonFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cryo Cell International (CCEL) Non-cash Items (2016 - 2025)

Historic Non-cash Items for Cryo Cell International (CCEL) over the last 15 years, with Q3 2025 value amounting to $15360.0.

  • Cryo Cell International's Non-cash Items fell 9593.19% to $15360.0 in Q3 2025 from the same period last year, while for Aug 2025 it was $15360.0, marking a year-over-year decrease of 9593.19%. This contributed to the annual value of $997943.0 for FY2024, which is 63741.45% up from last year.
  • Latest data reveals that Cryo Cell International reported Non-cash Items of $15360.0 as of Q3 2025, which was down 9593.19% from $425995.0 recorded in Q2 2025.
  • Cryo Cell International's Non-cash Items' 5-year high stood at $7.3 million during Q1 2021, with a 5-year trough of $15360.0 in Q3 2025.
  • Moreover, its 5-year median value for Non-cash Items was $377568.0 (2024), whereas its average is $1.2 million.
  • Its Non-cash Items has fluctuated over the past 5 years, first crashed by 9895.48% in 2022, then skyrocketed by 63741.45% in 2024.
  • Over the past 5 years, Cryo Cell International's Non-cash Items (Quarter) stood at $3.6 million in 2021, then plummeted by 98.95% to $37250.0 in 2022, then surged by 263.3% to $135330.0 in 2023, then surged by 637.41% to $997943.0 in 2024, then crashed by 98.46% to $15360.0 in 2025.
  • Its last three reported values are $15360.0 in Q3 2025, $425995.0 for Q2 2025, and $705134.0 during Q1 2025.